A Comparative Clinical Study of Kantakari Avaleha and Chitrakaharitaki Avaleha on Tamaka Shwasa (Bronchial Asthma) in Children

The study design of present clinical trial was open labelled, randomized controlled clinical trial. The clinical study was started after getting approval of IEC (vide ref. - PGT/7/-A/Ethics/2019-2020/3158 dated 30/03/2020). The trial is also registered in CTRI prospectively (CTRI/2020/06/025913 registered on: 1/06/2020). First enrolment was on 26/08/2020 and last patient enrolled on 21/10/2022. During this period, total 104 patients of Tamaka Shwasa have been screened, out of which 100 patients were registered in the study. Among them 80 were completed the trial along with follow-up and 20 patients didn’t complete the trial due to various reasons. In the present clinical trial, subjects were randomly allocated into two groups according to Sequentially numbered opaque sealed envelope (SNOSE). Group A: Kantakari Avaleha and group B: Chitraka Haritaki Avaleha. Drugs were given in below mentioned dose in three divided doses after meal with lukewarm water for a period of 8 weeks with 4 weeks of follow up. After 8 weeks, use of Kantakari Avaleha (Group A) showed statistical significant improvement in all the cardinal symptoms, Agni Bala, PEFR, RR, BHT, Level of Asthma control, ACT and in ACQ; while insignificant changes were seen in all haematological parameters except Total RBC count (which also remains in normal limit only). 

Chitrakaharitaki Avaleha (Group B) showed significant improvement in all the cardinal symptoms, Agni Bala, PEFR, RR, Level of Asthma control, ACT score and in total ACQ; while insignificant changes were seen in all haematological parameters except Basophil count.

On comparison of the groups, significant difference was found in Shwasakashtta, Pinasa, *Krichchhratbhashitam,*ACT and ACQ. (group B is better than group A)